Chapter 137
Lipoid Proteinosis and Heritable Disorders of Connective Tissue

Jonathan A. Dyer

REFERENCES

1. Beighton P et al: Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). *Am J Med Genet* ***77***(1):31-37, 1998
2. Furukawa K, Okajima T: Galactosyltransferase I is a gene responsible for progeroid variant of Ehlers-Danlos syndrome: Molecular cloning and identification of mutations. *Biochim Biophys Acta* ***1573***(3):377-381, 2002
3. Beighton P: Hypermobility scoring. *Br J Rheumatol* ***27***(2):163, 1988
4. Lawrence EJ: The clinical presentation of Ehlers-Danlos syndrome. *Adv Neonatal Care* ***5***(6):301-314, 2005
5. Wenstrup RJ et al: COL5A1 haploinsufficiency is a common molecular mechanism underlying the classical form of EDS. *Am J Hum Genet* ***66***(6):1766-1776, 2000
6. Symoens S et al: COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers-Danlos syndrome. *Hum Mutat* ***30***(2):E395-E403, 2009
7. Wenstrup RJ et al: A splice-junction mutation in the region of COL5A1 that codes for the carboxyl propeptide of pro alpha 1(V) chains results in the gravis form of the Ehlers-Danlos syndrome (type I). *Hum Mol Genet* ***5***(11):1733-1736, 1996
8. Greenspan DS et al: COL5A1: Fine genetic mapping and exclusion as candidate gene in families with nail-patella syndrome, tuberous sclerosis 1, hereditary hemorrhagic telangiectasia, and Ehlers-Danlos Syndrome type II. *Genomics* ***25***(3):737-739, 1995
9. Nuytinck L et al: Classical Ehlers-Danlos syndrome caused by a mutation in type I collagen. *Am J Hum Genet* ***66***(4):1398-1402, 2000
10. Malfait F et al: Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. *Hum Mutat* ***28***(4):387-395, 2007
11. Schwarze U et al: Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. *Am J Hum Genet* ***74***(5):917-930, 2004
12. Burch GH et al: Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. *Nat Genet* ***17***(1):104-108, 1997
13. Mao JR, Bristow J: The Ehlers-Danlos syndrome: on beyond collagens. *J Clin Invest* ***107***(9):1063-1069, 2001
14. Hausser I, Anton-Lamprecht I: Differential ultrastructural aberrations of collagen fibrils in Ehlers-Danlos syndrome types I-IV as a means of diagnostics and classification. *Hum Genet* ***93***(4):394-407, 1994
15. Grahame R, Beighton P: Physical properties of the skin in the Ehlers-Danlos syndrome. *Ann Rheum Dis* ***28***(3):246-251, 1969
16. Tiller GE et al: Aortic root dilatation in Ehlers-Danlos syndrome types I, II and III. A report of five cases. *Clin Genet* ***53***(6):460-465, 1998
17. Machet L et al: Absence of inferior labial and lingual frenula in ehlers-danlos syndrome: A minor diagnostic criterion in French patients. *Am J Clin Dermatol* ***11***(4):269-273, 2010
18. Pepin M et al: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. *N Engl J Med* ***342***(10):673-680, 2000
19. Wenstrup R, De PA: Ehlers-Danlos syndrome, classic type. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993, http://www.genetests.org
20. Snyder RR, Gilstrap LC, Hauth JC: Ehlers-Danlos syndrome and pregnancy. *Obstet Gynecol* ***61***(5):649-650, 1983
21. Ramos-E-Silva M et al: Connective tissue diseases: Pseudoxanthoma elasticum, anetoderma, and Ehlers-Danlos syndrome in pregnancy. *Clin Dermatol* ***24***(2):91-96, 2006
22. Wenstrup RJ et al: Prevalence of aortic root dilation in the Ehlers-Danlos syndrome. *Genet Med* ***4***(3):112-117, 2002

23. Narcisi P et al: A family with Ehlers-Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. *Hum Mol Genet* ***3***(9):1617-1620, 1994

24. Zweers MC et al: Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. *Am J Hum Genet* ***73***(1):214-217, 2003

25. Callewaert B et al: Ehlers-Danlos syndromes and Marfan syndrome. *Best Pract Res Clin Rheumatol* ***22***(1):165-189, 2008

26. Chen W et al: The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: Quadricuspid aortic valve and other midline defects. *Am J Med Genet A* ***149A***(12):2803-2808, 2009

27. Grahame R: Heritable disorders of connective tissue. *Baillieres Best Pract Res Clin Rheumatol* ***14***(2):345-361, 2000

28. Harinstein D et al: Systemic joint laxity (the hypermobile joint syndrome) is associated with temporomandibular joint dysfunction. *Arthritis Rheum* ***31***(10):1259-1264, 1988

29. Stoler JM, Oaklander AL: Patients with Ehlers Danlos syndrome and CRPS: A possible association? *Pain* ***123***(1-2):204-209, 2006

30. Lumley MA et al: Psychosocial functioning in the Ehlers-Danlos syndrome. *Am J Med Genet* ***53***(2):149-152, 1994

31. Levy HP. Ehlers-Danlos syndrome, hypermobility type. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993, http://www.genetests.org

32. Kobayasi T: Dermal elastic fibres in the inherited hypermobile disorders. *J Dermatol Sci* ***41***(3):175-185, 2006

33. McDonnell NB et al: Echocardiographic findings in classical and hypermobile Ehlers-Danlos syndromes. *Am J Med Genet A* ***140***(2):129-136, 2006

34. Castori M et al: Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: A pilot study on 21 patients. *Am J Med Genet A* ***152A***(3):556-564, 2010

35. Cole WG et al: A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. *J Biol Chem* ***265***(28):17070-17077, 1990

36. Germain DP: Clinical and genetic features of vascular Ehlers-Danlos syndrome. *Ann Vasc Surg* ***16***(3):391-397, 2002

37. Pinnell SR et al: A heritable disorder of connective tissue. Hydroxylysine-deficient collagen disease. *N Engl J Med* ***286***(19):1013-1020, 1972

38. Eyre DR, Glimcher MJ: Reducible crosslinks in hydroxylysine-deficient collagens of a heritable disorder of connective tissue. *Proc Natl Acad Sci U S A* ***69***(9):2594-2598, 1972

39. Heikkinen J et al: Duplication of seven exons in the lysyl hydroxylase gene is associated with longer forms of a repetitive sequence within the gene and is a common cause for the type VI variant of Ehlers-Danlos syndrome. *Am J Hum Genet* ***60***(1):48-56, 1997

40. Ogur G et al: Clinical, ultrastructural and biochemical studies in two sibs with Ehlers-Danlos syndrome type VI-B-like features. *Clin Genet* ***46***(6):417-422, 1994

41. Pasquali M et al: Urinary pyridinium cross-links: A noninvasive diagnostic test for Ehlers-Danlos syndrome type VI. *N Engl J Med* ***331***(2):132-133, 1994

42. Eyre D et al: The kyphoscoliotic type of Ehlers-Danlos syndrome (type VI): Differential effects on the hydroxylation of lysine in collagens I and II revealed by analysis of cross-linked telopeptides from urine. *Mol Genet Metab* ***76***(3):211-216, 2002

43. Giunta C et al: The arthrochalasia type of Ehlers-Danlos syndrome (EDS VIIA and VIIB): The diagnostic value of collagen fibril ultrastructure. *Am J Med Genet A* ***146A***(10):1341-1346, 2008

44. Byers PH et al: Ehlers-Danlos syndrome type VIIA and VIIB result from splice-junction mutations or genomic deletions that involve exon 6 in the COL1A1 and COL1A2 genes of type I collagen. *Am J Med Genet* ***72***(1):94-105, 1997

45. Ho KK et al: Further evidence that the failure to cleave the aminopropeptide of type I procollagen is the cause of Ehlers-Danlos syndrome type VII. *Hum Mutat* ***3***(4):358-364, 1994

46. Nicholls AC et al: Clinical phenotypes and molecular characterisation of three patients with Ehlers-Danlos syndrome type VII. *J Med Genet* ***37***(11):E33, 2000

47. Giunta C et al: Ehlers-Danlos syndrome type VII: Clinical features and molecular defects. *J Bone Joint Surg Am* ***81***(2):225-238, 1999

48. Lehmann HW et al: Ehlers-Danlos syndrome type VII: Phenotype and genotype. *Arch Dermatol Res* ***286***(8):425-428, 1994

49. Colige A et al: Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. *Am J Hum Genet* ***65***(2):308-317, 1999

50. Colige A et al: Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (Type VIIC) and common polymorphisms in the ADAMTS2 gene. *J Invest Dermatol* ***123***(4):656-663, 2004

51. Smith LT et al: Human dermatosparaxis: A form of Ehlers-Danlos syndrome that results from failure to remove the amino-terminal propeptide of type I procollagen. *Am J Hum Genet* ***51***(2):235-244, 1992

52. Petty EM et al: Dermatosparaxis in children. A case report and review of the newly recognized phenotype. *Arch Dermatol* ***129***(10):1310-1315, 1993

53. Fujimoto A, Wilcox WR, Cohn DH: Clinical, morphological, and biochemical phenotype of a new case of Ehlers-Danlos syndrome type VIIC. *Am J Med Genet* ***68***(1):25-28, 1997

54. Coman DJ: Diagnostic dilemma's: the congenital disorders of glycosylation are clinical chameleons. *Eur J Hum Genet* ***16***(1):2-4, 2008

55. Makareeva E et al: Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: Unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. *J Biol Chem* ***28***(10):6463-6470, 2006

56. Okajima T et al: Molecular basis for the progeroid variant of Ehlers-Danlos syndrome. Identification and characterization of two mutations in galactosyltransferase I gene. *J Biol Chem* ***274***(41):28841-28844, 1999

57. Sheen VL et al: Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. *Neurology* ***64***(2):254-262, 2005

58. Kosho T et al: A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations. *Am J Med Genet A* ***152A***(6):1333-1346, 2010

59. Giunta C et al: Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome–an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13. *Am J Hum Genet* ***82***(6):1290-1305, 2008

60. Loeys BL, Dietz HC: Loeys–Dietz syndrome. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993, http://www.genetests.org

61. Hoornaert KP et al: Stickler syndrome caused by COL2A1 mutations: Genotype-phenotype correlation in a series of 100 patients. *Eur J Hum Genet* ***18***(8):872-880, 2010

62. Rose PS et al: Stickler syndrome: Clinical characteristics and diagnostic criteria. *Am J Med Genet A* ***138A***(3):199-207, 2005

63. Morris CA, Mervis CB: Williams syndrome and related disorders. *Annu Rev Genomics Hum Genet* ***1***:461-484, 2000

64. Pasteris NG et al: Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: A putative Rho/Rac guanine nucleotide exchange factor. *Cell* ***79***(4):669-678, 1994

65. Orrico A et al: Aarskog-Scott syndrome: Clinical update and report of nine novel mutations of the FGD1 gene. *Am J Med Genet A* ***152A***(2):313-318, 2010

66. Syx D et al: The RIN2 syndrome: A new autosomal recessive connective tissue disorder caused by deficiency of Ras and Rab interactor 2 (RIN2). *Hum Genet* ***128***(1):79-88, 2010

67. Basel-Vanagaite L et al: RIN2 deficiency results in macrocephaly, alopecia, cutis laxa, and scoliosis: MACS syndrome. *Am J Hum Genet* ***85***(2):254-263, 2009

68. Whitelaw SE: Ehlers-Danlos Syndrome, classical type: Case management. *Pediatr Nurs* ***29***(6):423-426, 2003

69. Whitelaw SE: Ehlers-Danlos syndrome, classical type: Case management. *Dermatol Nurs* ***16***(5):433-436, 449, 2004

70. Ehlers-Danlos National Foundation. 2010, www.ednf.org

71. Brooke BS et al: Contemporary management of vascular complications associated with Ehlers-Danlos syndrome. *J Vasc Surg* ***51***(1):131-138, 2010

72. Voermans NC et al: Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos syndrome. *Semin Arthritis Rheum* ***40***(3):267-274, 2010

73. Voermans NC et al: Neuromuscular involvement in various types of Ehlers-Danlos syndrome. *Ann Neurol* ***65***(6):687-697, 2009

74. Pyeritz RE: The Marfan syndrome. *Annu Rev Med* ***51***:481-510, 2000

75. Rantamaki T et al: Recurrence of Marfan syndrome as a result of parental germ-line mosaicism for an FBN1 mutation. *Am J Hum Genet* ***64***(4):993-1001, 1999

76. Faivre L et al: Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. *Pediatrics* ***123***(1):391-398, 2009

77. Pearson GD et al: Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders. *Circulation* ***118***(7):785-791, 2008

78. Lindeman JH et al: Distinct defects in collagen microarchitecture underlie vessel-wall failure in advanced abdominal aneurysms and aneurysms in Marfan syndrome. *Proc Natl Acad Sci U S A* ***107***(2):862-865, 2010

79. Dietz HC, Pyeritz RE: Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. *Hum Mol Genet* 4(Spec No):1799-1809, 1995

80. Dietz HC et al: Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. *Nature* ***352***(6333):337-339, 1991

81. Robinson PN et al: The molecular genetics of Marfan syndrome and related disorders. *J Med Genet* ***43***(10):769-787, 2006

82. Ramirez F: Fibrillln mutations in Marfan syndrome and related phenotypes. *Curr Opin Genet Dev* ***6***(3):309-315, 1996

83. Goumans MJ, Liu Z, ten DP: TGF-beta signaling in vascular biology and dysfunction. *Cell Res* ***19***(1):116-127, 2009

84. Jones JA, Ikonomidis JS: The pathogenesis of aortopathy in Marfan syndrome and related diseases. *Curr Cardiol Rep* ***12***(2):99-107, 2010

85. Rybczynski M et al: The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome. *Am J Med Genet A* ***146A***(24):3157-3166, 2008

86. Joseph KN et al: Orthopedic aspects of the Marfan phenotype. *Clin Orthop Relat Res* (277):251-261, 1992

87. Maumenee IH: The eye in the Marfan syndrome. *Trans Am Ophthalmol Soc* ***79***:684-733, 1981

88. Jeremy RW et al: Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. *Am J Cardiol* ***74***(4):369-373, 1994

89. Groenink M et al: Survival and complication free survival in Marfan's syndrome: Implications of current guidelines. *Heart* ***82***(4):499-504, 1999

90. Silverman DI et al: Life expectancy in the Marfan syndrome. *Am J Cardiol* ***75***(2):157-160, 1995

91. Seliem MA et al: Echocardiographic evaluation of the aortic root and mitral valve in children and adolescents with isolated pectus excavatum: Comparison with Marfan patients. *Pediatr Cardiol* ***13***(1):20-23, 1992

92. Ho NC, Tran JR, Bektas A: Marfan's syndrome. *Lancet* ***366***(9501):1978-1981, 2005

93. De PA et al: Revised diagnostic criteria for the Marfan syndrome. *Am J Med Genet* ***62***(4):417-426, 1996

94. Morse RP et al: Diagnosis and management of infantile marfan syndrome. *Pediatrics* ***86***(6):888-895, 1990

95. Buntinx IM et al: Neonatal Marfan syndrome with congenital arachnodactyly, flexion contractures, and severe cardiac valve insufficiency. *J Med Genet* ***28***(4):267-273, 1991

96. Gupta PA et al: Ten novel FBN2 mutations in congenital contractural arachnodactyly: Delineation of the molecular pathogenesis and clinical phenotype. *Hum Mutat* ***19***(1):39-48, 2002

97. Callewaert BL et al: Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: Report of 14 novel mutations and review of the literature. *Hum Mutat* ***30***(3):334-341, 2009

98. Dietz HC. Marfan syndrome, www.ednf.org, 1993

99. Arn PH et al: Outcome of pectus excavatum in patients with Marfan syndrome and in the general population. *J Pediatr* ***115***(6):954-958, 1989

100. Shores J et al: Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med* ***330***(19):1335-1341, 1994

101. Gray JR et al: Life expectancy in British Marfan syndrome populations. *Clin Genet* ***54***(2):124-128, 1998

102. Brooke BS et al: Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med* ***358***(26):2787-2795, 2008

103. Hall JR et al: Pneumothorax in the Marfan syndrome: Prevalence and therapy. *Ann Thorac Surg* ***37***(6):500-504, 1984

104. Yap S: Classical homocystinuria: Vascular risk and its prevention. *J Inherit Metab Dis* ***26***(2-3):259-265, 2003

105. Naughten ER, Yap S, Mayne PD: Newborn screening for homocystinuria: Irish and world experience. *Eur J Pediatr* ***157***(Suppl. 2):S84-S87, 1998

106. Skovby F, Gaustadnes M, Mudd SH: A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency. *Mol Genet Metab* ***99***(1):1-3, 2010

107. Munke M et al: The gene for cystathionine beta-synthase (CBS) maps to the subtelomeric region on human chromosome 21q and to proximal mouse chromosome 17. *Am J Hum Genet* ***42***(4):550-559, 1988

108. Miles EW, Kraus JP: Cystathionine beta-synthase: Structure, function, regulation, and location of homocystinuria-causing mutations. *J Biol Chem* ***279***(29):29871-29874, 2004

109. Kraus JP et al: Cystathionine beta-synthase mutations in homocystinuria. *Hum Mutat* ***13***(5):362-375, 1999

110. Urreizti R et al: The p.T191M mutation of the CBS gene is highly prevalent among homocystinuric patients from Spain, Portugal and South America. *J Hum Genet* ***51***(4):305-313, 2006

111. Hu FL et al: Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. *Hum Mol Genet* ***2***(11):1857-1860, 1993

112. Gallagher PM et al: High frequency (71%) of cystathionine beta-synthase mutation G307S in Irish homocystinuria patients. *Hum Mutat* ***6***(2):177-180, 1995

113. Hubmacher D et al: Functional consequences of homocysteinylation of the elastic fiber proteins fibrillin-1 and tropoelastin. *J Biol Chem* ***285***(2):1188-1198, 2010

114. de Franchis R et al: Clinical aspects of cystathionine beta-synthase deficiency: How wide is the spectrum? The Italian Collaborative Study Group on Homocystinuria. *Eur J Pediatr* ***157***(Suppl. 2):S67-S70, 1998

115. Mudd SH et al: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. *Am J Hum Genet* ***37***(1):1-31, 1985

116. Tan WH et al: Isolated sulfite oxidase deficiency: A case report with a novel mutation and review of the literature. *Pediatrics* ***116***(3):757-766, 2005

117. Lerner-Ellis JP et al: Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. *Nat Genet* ***38***(1):93-100, 2006

118. Morel CF, Lerner-Ellis JP, Rosenblatt DS: Combined methylmalonic aciduria and homocystinuria (cblC): Phenotype-genotype correlations and ethnic-specific observations. *Mol Genet Metab* ***88***(4):315-321, 2006

119. Picker JD, Levy HL: Homocystinuria caused by cystathionine beta-synthase deficiency. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993, http://www.genetests.org

120. Chen X et al: Contrasting behaviors of mutant cystathionine beta-synthase enzymes associated with pyridoxine response. *Hum Mutat* ***27***(5):474-482, 2006

121. Lawson-Yuen A, Levy HL: The use of betaine in the treatment of elevated homocysteine. *Mol Genet Metab* ***88***(3):201-207, 2006

122. Yaghmai R et al: Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. *Am J Med Genet* ***108***(1):57-63, 2002

123. Martin L et al: Heterozygosity for a single mutation in the ABCC6 gene may closely mimic PXE: Consequences of this phenotype overlap for the definition of PXE. *Arch Dermatol* ***144***(3):301-306, 2008

124. Uitto J, Jiang Q: Pseudoxanthoma elasticum-like phenotypes: More diseases than one. *J Invest Dermatol* ***127***(3):507-510, 2007

125. Jiang Q et al: Pseudoxanthoma elasticum is a metabolic disease. *J Invest Dermatol* ***129***(2):348-354, 2009

126. Li Q et al: Pseudoxanthoma elasticum: Clinical phenotypes, molecular genetics and putative pathomechanisms. *Exp Dermatol* ***18***(1):1-11, 2009

127. Le SO et al: Evidence for a founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa. *Hum Genet* ***111***(4-5):331-338, 2002

128. Jiang Q et al: Parabiotic heterogenetic pairing of Abcc6-/-/Rag1-/- mice and their wild-type counterparts halts ectopic mineralization in a murine model of pseudoxanthoma elasticum. *Am J Pathol* ***176***(4):1855-1862, 2010

129. Vanakker OM et al: Low serum vitamin K in PXE results in defective carboxylation of mineralization inhibitors similar to the GGCX mutations in the PXE-like syndrome. *Lab Invest* ***90***(6):895-905, 2010

130. Lebwohl M et al: Classification of pseudoxanthoma elasticum: Report of a consensus conference. *J Am Acad Dermatol* ***30***(1):103-107, 1994

131. Kazakis AM, Parish WR: Periumbilical perforating pseudoxanthoma elasticum. *J Am Acad Dermatol* ***19***(2 Pt 2):384-388, 1988

132. Lebwohl M et al: Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesions. *N Engl J Med* ***317***(6):347-350, 1987

133. Hellemans J et al: Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. *Nat Genet* ***36***(11):1213-1218, 2004

134. Neldner KH, Martinez-Hernandez A: Localized acquired cutaneous pseudoxanthoma elasticum. *J Am Acad Dermatol* ***1***(6):523-530, 1979

135. Karp DL et al: A yellow plaque with keratotic papules on the abdomen. Perforating calcific elastosis (periumbilical perforating pseudoxanthoma elasticum [PXE], localized acquired cutaneous PXE). *Arch Dermatol* ***132***(2):224-228, 1996

136. Becuwe C et al: Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. *Dermatology* ***210***(1):60-63, 2005

137. Lewis KG et al: Acquired disorders of elastic tissue: Part II. decreased elastic tissue. *J Am Acad Dermatol* ***51***(2):165-185, 2004

138. Li TH et al: An unusual cutaneous manifestation of pseudoxanthoma elasticum mimicking reticulate pigmentary disorders. *Br J Dermatol* ***134***(6):1157-1159, 1996

139. Viljoen DL et al: Pseudoxanthoma elasticum in South Africa–genetic and clinical implications. *S Afr Med J* ***66***(21):813-816, 1984

140. Naouri M et al: Manifestations of pseudoxanthoma elasticum in childhood. *Br J Dermatol* ***161***(3):635-639, 2009

141. Georgalas I et al: Angioid streaks, clinical course, complications, and current therapeutic management. *Ther Clin Risk Manag* ***5***(1):81-89, 2009

142. Nishida H et al: Coronary artery bypass in a 15-year-old girl with pseudoxanthoma elasticum. *Ann Thorac Surg* ***49***(3):483-485, 1990

143. Viljoen DL, Beatty S, Beighton P: The obstetric and gynaecological implications of pseudoxanthoma elasticum. *Br J Obstet Gynaecol* ***94***(9):884-888, 1987

144. Bowen AR et al: Pseudoxanthoma elasticum-like fibers in the inflamed skin of patients without pseudoxanthoma elasticum. *J Cutan Pathol* ***34***(10):777-781, 2007

145. Hacker SM et al: Juvenile pseudoxanthoma elasticum: Recognition and management. *Pediatr Dermatol* ***10***(1):19-25, 1993

146. Suarez MJ et al: Sonographic aspects of pseudoxanthoma elasticum. *Pediatr Radiol* ***21***(7):538-539, 1991

147. Aessopos A, Farmakis D, Loukopoulos D: Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. *Blood* ***99***(1):30-35, 2002

148. Coatesworth AP et al: A case of systemic pseudopseudoxanthoma elasticum with diverse symptomatology caused by long-term penicillamine use. *J Clin Pathol* ***51***(2):169-171, 1998

149. Lewis KG et al: Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. *J Cutan Pathol* ***33***(10):695-700, 2006

150. Farmakis D et al: Aortic valve replacement in a patient with thalassemia intermedia. *Ann Thorac Surg* ***81***(2):737-739, 2006

151. Laube S, Moss C: Pseudoxanthoma elasticum. *Arch Dis Child* ***90***(7):754-756, 2005

152. Viljoen DL, Bloch C, Beighton P: Plastic surgery in pseudoxanthoma elasticum: Experience in nine patients. *Plast Reconstr Surg* ***85***(2):233-238, 1990

153. Cunningham JR et al: Pseudoxanthoma elasticum: Treatment of gastrointestinal hemorrhage by arterial embolization and observations on autosomal dominant inheritance. *Johns Hopkins Med J* ***147***(4):168-173, 1980

154. Browning AC et al: Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: One-year results of a prospective case series. *Ophthalmology* ***112***(7):1227-1231, 2005

155. Lommatzsch A: Management of choroidal vascularisation. *Br J Ophthalmol* ***92***(4):445-446, 2008

156. Hamamoto Y et al: Hyperreactivity of pseudoxanthoma elasticum-affected dermis to vitamin D3. *J Am Acad Dermatol* ***42***(4):685-687, 2000

157. Sherer DW et al: Oral phosphate binders in the treatment of pseudoxanthoma elasticum. *J Am Acad Dermatol* ***53***(4):610-615, 2005

158. Takata T et al: Treatment of pseudoxanthoma elasticum with tocopherol acetate and ascorbic acid. *Pediatr Dermatol* ***24***(4):424-425, 2007

159. Li Q et al: Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum. *Clin Transl Sci* ***2***(6):398-404, 2009

160. LaRusso J et al: Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)). *J Invest Dermatol* ***129***(6):1388-1394, 2009

161. Graul-Neumann LM et al: Highly variable cutis laxa resulting from a dominant splicing mutation of the elastin gene. *Am J Med Genet A* ***146A***(8):977-983, 2008

162. Urban Z et al: Autosomal dominant cutis laxa with severe lung disease: Synthesis and matrix deposition of mutant tropoelastin. *J Invest Dermatol* ***124***(6):1193-1199, 2005

163. Beighton P: The dominant and recessive forms of cutis laxa. *J Med Genet* ***9***(2):216-221, 1972

164. Damkier A, Brandrup F, Starklint H: Cutis laxa: Autosomal dominant inheritance in five generations. *Clin Genet* ***39***(5):321-329, 1991

165. Markova D et al: Genetic heterogeneity of cutis laxa: A heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. *Am J Hum Genet* ***72***(4):998-1004, 2003

166. Kielty CM: Elastic fibres in health and disease. *Expert Rev Mol Med* ***8***(19):1-23, 2006

167. Morava E et al: Autosomal recessive cutis laxa syndrome revisited. *Eur J Hum Genet* ***17***(9):1099-1110, 2009

168. Ringpfeil F: Selected disorders of connective tissue: Pseudoxanthoma elasticum, cutis laxa, and lipoid proteinosis. *Clin Dermatol* ***23***(1):41-46, 2005

169. Hu Q et al: Fibulin-5 mutations: Mechanisms of impaired elastic fiber formation in recessive cutis laxa. *Hum Mol Genet* ***15***(23):3379-3386, 2006

170. Hucthagowder V et al: Fibulin-4: A novel gene for an autosomal recessive cutis laxa syndrome. *Am J Hum Genet* ***78***(6):1075-1080, 2006

171. Reversade B et al: Mutations in PYCR1 cause cutis laxa with progeroid features. *Nat Genet* ***41***(9):1016-1021, 2009

172. Morava E et al: Defining the phenotype in an autosomal recessive cutis laxa syndrome with a combined congenital defect of glycosylation. *Eur J Hum Genet* ***16***(1):28-35, 2008

173. Kornak U et al: Impaired glycosylation and cutis laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. *Nat Genet* ***40***(1):32-34, 2008

174. Hennies HC et al: Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. *Nat Genet* ***40***(12):1410-1412, 2008

175. Kivuva EC et al: De Barsy syndrome: A review of the phenotype. *Clin Dysmorphol* ***17***(2):99-107, 2008

176. Gupta N, Phadke SR: Cutis laxa type II and wrinkly skin syndrome: Distinct phenotypes. *Pediatr Dermatol* ***23***(3):225-230, 2006

177. Urban Z et al: Mutations in LTBP4 cause a syndrome of impaired pulmonary, gastrointestinal, genitourinary, musculoskeletal, and dermal development. *Am J Hum Genet* ***85***(5):593-605, 2009

178. Valayannopoulos V et al: Transaldolase deficiency: A new cause of hydrops fetalis and neonatal multi-organ disease. *J Pediatr* ***149***(5):713-717, 2006

179. Bouloc A et al: Increased fibroblast elastase activity in acquired cutis laxa. *Dermatology* ***198***(4):346-350, 1999

180. Hu Q et al: Inflammatory destruction of elastic fibers in acquired cutis laxa is associated with missense alleles in the elastin and fibulin-5 genes. *J Invest Dermatol* ***126***(2):283-290, 2006

181. Uenishi T et al: Pseudoxanthoma elasticum with generalized cutaneous laxity. *Arch Dermatol* ***133***(5):664-666, 1997

182. Vanakker OM et al: Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. *J Invest Dermatol* ***127***(3):581-587, 2007

183. Bangsgaard N et al: Nephrogenic systemic fibrosis: Late skin manifestations. *Arch Dermatol* ***145***(2):183-187, 2009

184. Haider M et al: Acquired cutis laxa type II (Marshall syndrome) in an 18-month-old child: A case report. *Pediatr Dermatol* ***27***(1):89-91, 2010

185. Muster AJ et al: Fatal cardiovascular disease and cutis laxa following acute febrile neutrophilic dermatosis. *J Pediatr* ***102***(2):243-248, 1983

186. Hill VA, Seymour CA, Mortimer PS: Pencillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease. *Br J Dermatol* ***142***(3):560-561, 2000

187. Mahajan VK, Sharma NL, Garg G: Cutis laxa acquisita associated with cutaneous mastocytosis. *Int J Dermatol* ***45***(8):949-951, 2006

188. Kiuru-Enari S, Keski-Oja J, Haltia M: Cutis laxa in hereditary gelsolin amyloidosis. *Br J Dermatol* ***152***(2):250-257, 2005

189. Linares A et al: Reversible cutis laxa due to maternal D-penicillamine treatment. *Lancet* ***2***(8132):43, 1979

190. Solomon L et al: Neonatal abnormalities associated with D-penicillamine treatment during pregnancy. *N Engl J Med* ***296***(1):54-55, 1977

191. Nahas FX et al: The role of plastic surgery in congenital cutis laxa: A 10-year follow-up. *Plast Reconstr Surg* ***104***(4):1174-1178, 1999

192. Fisher BK, Page E, Hanna W: Acral localized acquired cutis laxa. *J Am Acad Dermatol* ***21***(1):33-40, 1989

193. Tamura BM et al: Cutis laxa: Improvement of facial aesthetics by using botulinum toxin. *Dermatol Surg* ***30***(12 Pt 2):1518-1520, 2004

194. Hirano E et al: Functional rescue of elastin insufficiency in mice by the human elastin gene: Implications for mouse models of human disease. *Circ Res* ***101***(5):523-531, 2007

195. Steiner RD, Pepin MG, Byers PH: Osteogenesis imperfecta. In: GeneReviews at GeneTests: Medical Genetics Information Resource. Seattle, University of Washington, 1993, http://www.genetests.org

196. Tinkle BT, Wenstrup RJ: A genetic approach to fracture epidemiology in childhood. *Am J Med Genet C Semin Med Genet* ***139C***(1):38-54, 2005

197. Stevenson CJ, Bottoms E, Shuster S: Skin collagen in osteogenesis imperfecta. *Lancet* ***1***(7652):860-861, 1970

198. Prockop DJ: Osteogenesis imperfecta: Phenotypic heterogeneity, protein suicide, short and long collagen. *Am J Hum Genet* ***36***(3):499-505, 1984

199. Hansen B, Jemec GB: The mechanical properties of skin in osteogenesis imperfecta. *Arch Dermatol* ***138***(7):909-911, 2002

200. Barnes AM et al: Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. *N Engl J Med* ***362***(6):521-528, 2010

201. Alanay Y et al: Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. *Am J Hum Genet* ***86***(4):551-559, 2010

202. Gahagan S, Rimsza ME: Child abuse or osteogenesis imperfecta: How can we tell? *Pediatrics* ***88***(5):987-992, 1991

203. Glorieux FH: Osteogenesis imperfecta. *Best Pract Res Clin Rheumatol* ***22***(1):85-100, 2008

204. Marini JC et al: The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. *J Clin Endocrinol Metab* ***76***(1):251-256, 1993

205. Cheung MS, Glorieux FH: Osteogenesis Imperfecta: Update on presentation and management. *Rev Endocr Metab Disord* ***9***(2):153-160, 2008

206. Le BK et al: Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. *Transplantation* ***79***(11):1607-1614, 2005

207. Gass JK et al: Buschke-Ollendorff syndrome: A manifestation of a heterozygous nonsense mutation in the LEMD3 gene. *J Am Acad Dermatol* ***58***(5 Suppl. 1):S103-S104, 2008

208. Schena D et al: Buschke-Ollendorff syndrome. *Int J Dermatol* ***47***(11):1159-1161, 2008

209. Hellemans J et al: Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis. *Hum Mutat* ***27***(3):290, 2006

210. Van Hougenhouck-Tulleken W et al: Clinical and molecular characterization of lipoid proteinosis in Namaqualand, South Africa. *Br J Dermatol* ***151***(2):413-423, 2004

211. Hamada T et al: Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation. *J Invest Dermatol* ***120***(3):345-350, 2003

212. Sercu S et al: ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain. *Matrix Biol* ***28***(3):160-169, 2009

213. Fujimoto N et al: Extracellular matrix protein 1 interacts with the domain III of fibulin-1C and 1D variants through its central tandem repeat 2. *Biochem Biophys Res Commun* ***333***(4):1327-1333, 2005

214. Dyer JA, Yu QC, Paller AS: "Free-floating" desmosomes in lipoid proteinosis: An inherent defect in keratinocyte adhesion? *Pediatr Dermatol* ***23***(1):1-6, 2006

215. Sercu S et al: Functional redundancy of extracellular matrix protein 1 in epidermal differentiation. *Br J Dermatol* ***157***(4):771-775, 2007

216. Chan I: The role of extracellular matrix protein 1 in human skin. *Clin Exp Dermatol* ***29***(1):52-56, 2004

217. Kowalewski C et al: Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus. *J Dermatol Sci* ***38***(3):215-224, 2005

218. Oyama N et al: Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. *Lancet* ***362***(9378):118-123, 2003

219. Hamada T: Lipoid proteinosis. *Clin Exp Dermatol* ***27***(8):624-629, 2002

220. Sargenti NS, Batista JD, Durighetto AJ: A case of oral recurrent ulcerative lesions in a patient with lipoid proteinosis (Urbach-Wiethe disease). *Br J Oral Maxillofac Surg* ***48***(8):654-655, 2009

221. Cote DN: Head and neck manifestations of lipoid proteinosis. *Otolaryngol Head Neck Surg* ***119***(1):144-145, 1998

222. Siebert M, Markowitsch HJ, Bartel P: Amygdala, affect and cognition: Evidence from 10 patients with Urbach-Wiethe disease. *Brain* ***126***(Pt 12):2627-2637, 2003

223. Paller AS: Histology of lipoid proteinosis. *JAMA* ***272***(7):564-565, 1994

224. Ko C, Barr RJ: Vesicular lesions in a patient with lipoid proteinosis: A probable acantholytic dermatosis. *Am J Dermatopathol* ***25***(4):335-337, 2003

225. Teive HA et al: Generalized dystonia and striatal calcifications with lipoid proteinosis. *Neurology* ***63***(11):2168-2169, 2004

226. Chan I et al: Rapid diagnosis of lipoid proteinosis using an anti-extracellular matrix protein 1 (ECM1) antibody. *J Dermatol Sci* ***35***(2):151-153, 2004

227. Ozkaya-Bayazit E et al: [Oral DMSO therapy in 3 patients with lipoidproteinosis. Results of long-term therapy]. *Hautarzt* ***48***(7):477-481, 1997

228. Toosi S, Ehsani AH: Treatment of lipoid proteinosis with acitretin: A case report. *J Eur Acad Dermatol Venereol* ***23***(4):482-483, 2009

229. Haneke E et al: Hyalinosis cutis et mucosae in siblings. *Hum Genet* ***68***(4):342-345, 1984

230. Rosenthal G et al: Carbon dioxide laser treatment for lipoid proteinosis (Urbach-Wiethe syndrome) involving the eyelids. *Br J Ophthalmol* ***81***(3):253, 1997